Sight Sciences, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$12.6M
Doctors Paid
12,432
Transactions
40,530
2024 Total
$1.3M
Payment Breakdown by Category
Research$5.4M (43.0%)
Consulting$3.2M (25.0%)
Food & Beverage$1.8M (14.4%)
Travel$164,362 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.4M | 447 | 43.0% |
| Consulting Fee | $3.2M | 1,755 | 25.0% |
| Food and Beverage | $1.8M | 36,727 | 14.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.7M | 994 | 13.8% |
| Compensation for serving as faculty or as a speaker for a medical education program | $217,817 | 78 | 1.7% |
| Travel and Lodging | $164,362 | 515 | 1.3% |
| Grant | $75,000 | 9 | 0.6% |
| Education | $15,000 | 1 | 0.1% |
| Current or prospective ownership or investment interest | $6,570 | 3 | 0.1% |
| Honoraria | $3,500 | 1 | 0.0% |
Payments by Type
General
$7.2M
40,083 transactions
Research
$5.4M
443 transactions
Ownership
$0
4 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Prospective Randomized Masked Controlled Trial to Evaluate the Safety and Effectiveness of the TearCare System in the Treatment of the Signs and Symptoms of Dry Eye Disease (SAHARA) | $2.3M | 2 | 108 |
| Randomized Controlled Trial to Evaluate the Safety and Effectiveness of the TearCare System in the Treatment of the Signs and Symptoms of Dry Eye Disease | $820,224 | 2 | 42 |
| Prospective Multicenter Post Market Study of Use of the OMNI Surgical System in Combination with Cataract Extraction in Open Angle Glaucoma | $352,798 | 0 | 33 |
| A Prospective Multicenter Study of the OMNI Surgical System in Pseudophakic Eyes with Open Angle Glaucoma (ORION) | $319,654 | 1 | 17 |
| Prospective Multicenter Post Market Study of Use of the OMNI Surgical System in Combination with Cataract Extraction in Open Angle Glaucoma (GEMINI) | $186,708 | 1 | 19 |
| Prospective Multi-Center Post-Market Study of Use of the OMNI Surgical System in Combination With Cataract Extraction in Open Angle Glaucoma | $181,606 | 0 | 10 |
| A Retrospective Observational Multicenter 12-Month Follow-Up Study Of Patients With Open-Angle Glaucoma Treated With The Omni Surgical System As A Standalone Procedure In Pseudophakic Patients Or Combined With Cataract Surgery (ROMEO II) | $165,545 | 3 | 21 |
| An Observational Multicenter Clinical Study to Assess the Long-term Safety and Effectiveness of the OMNI Surgical System in Combination with Cataract Surgery in Eyes with Open Angle Glaucoma (GEMINI 2.0) | $136,790 | 3 | 24 |
| An Observational Multicenter Clinical Study to Assess the Safety and Effectiveness of the OMNI Surgical System in Pseudophakic Eyes with Primary Open Angle Glaucoma (ORION 2.0) | $97,268 | 1 | 27 |
| An observational multicenter clinical study to assess the long-term safety and effectiveness of the OMNI Surgical System in combination with cataract surgery in eyes with open angle glaucoma (GEMINI 2.0) | $97,211 | 2 | 20 |
| A Single Center Case Series Comparison of Signs and Symptoms Pre- and Post- Tearcare Treatment | $94,633 | 0 | 5 |
| A Retrospective Observational Multicenter 12 Month Follow Up Study of Patients with Open Angle Glaucoma Treated with the OMNI Surgical System as a Standalone Procedure in Pseudophakic Patients or Combined with Cataract Surgery (ROMEO) | $54,640 | 2 | 27 |
| TearCare vs. Warm Compress | $52,086 | 1 | 7 |
| Real World Efficacy of Canaloplasty and Trabeculotomy For Treatment of Glaucoma | $38,500 | 1 | 3 |
| Impact of Tear Care on reading speed in patients with Dry Eye Disease (DED) | $37,894 | 0 | 3 |
| Multi-Center Prospective Randomized Controlled Clinical Evaluation of the Safety and Effectiveness of the Sight Sciences VISCO360 Viscosurgical System in Canaloplasty Versus Selective Laser Trabeculoplasty in the Reduction of IOP in Primary Open Angle Glaucoma | $35,748 | 1 | 14 |
| Medication Reduction in Patients with Open Angle Glaucoma Undergoing Viscodilation of Schlemms Canal | $35,567 | 0 | 2 |
| A Retrospective Observational Multicenter Study of Patients with Open-Angle Glaucoma Treated with the OMNI Surgical System Previously Treated with a Trabecular Microbypass Stent (TREY) | $32,500 | 1 | 13 |
| Study of the TearCare System in Dry Eye Disease | $32,035 | 0 | 4 |
| VISCO360 vs. SLT | $31,896 | 1 | 2 |
| TRAB360 Retrospective Study | $28,820 | 0 | 3 |
| A Single Center Case Series Comparison of Signs and Symptoms Pre- and Post-Tearcare Treatment | $26,633 | 0 | 1 |
| A Single Center Case Series Comparison of Signs and Symptoms Peri-Cataract Surgery in Patients having TerCare with Expression. (SECURE) | $26,633 | 0 | 1 |
| PRECISION | $26,308 | 0 | 4 |
| Efficacy of canaloplasty and trabeculotomy in pseudophakic eyes with open-angle glaucoma | $26,000 | 0 | 1 |
| A Multicenter Retrospective Study on 3 Month Outcomes of Pseudophakic Viscodilation and Trabeculotomy in Patients with Mild to Moderate Glaucoma | $26,000 | 0 | 2 |
| A Retrospective Observational Multi-Center 12-month Follow-up Study of Patients with Open-Angle Glaucoma Treated with the OMNI Surgical System as a Standalone Procedure in Pseudophakic Patients or Combined with Cataract Surgery (ROMEO) | $24,900 | 1 | 7 |
| A Single Center Retrospective Trial of TearCare in Treating the Signs and Symptoms of Dry Eye Disease | $21,830 | 0 | 2 |
| Impact of TearCare on Reading Speed | $18,947 | 0 | 1 |
| A Prospective Multi-center Randomized Controlled Masked Post-market Study of use of the OMNI Surgical System in Combination with Cataract Extraction in Open Angle Glaucoma (VERITA) | $18,500 | 1 | 6 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Jai Parekh, M.d, M.D | Ophthalmology | Woodland Park, NJ | $438,315 | $0 |
| Thomas Chester, O.d, O.D | Optometrist | Cleveland, OH | $167,037 | $0 |
| Derek Cunningham, O.d, O.D | Optometrist | Austin, TX | $144,383 | $0 |
| Dr. Steven Vold, M.d, M.D | Ophthalmology | Winter Garden, FL | $143,109 | $0 |
| Dr. Nathan Radcliffe, M.d, M.D | Ophthalmology | New York, NY | $132,519 | $0 |
| Louis Cantor, Md, MD | Ophthalmology | Indianapolis, IN | $131,705 | $0 |
| Kristopher May, Od, OD | Optometrist | Coldwater, MS | $127,082 | $0 |
| Dr. Anthony Realini, M.d, M.D | Ophthalmology | Morgantown, WV | $120,791 | $0 |
| Preeya Gupta, Md, MD | Ophthalmology | Raleigh, NC | $117,666 | $0 |
| Kuldev Singh, Md, MD | Ophthalmology | Stanford, CA | $113,678 | $0 |
| Arkadiy Yadgarov | Ophthalmology | Atlanta, GA | $102,547 | $0 |
| Dr. Steven Sarkisian, Md, MD | Ophthalmology | Oklahoma City, OK | $101,105 | $0 |
| Damon Dierker, O.d, O.D | Optometrist | Indianapolis, IN | $98,502 | $0 |
| Brian Flowers, M.d, M.D | Glaucoma Specialist | Fort Worth, TX | $95,765 | $0 |
| Inder Singh | Ophthalmology | Racine, WI | $90,597 | $0 |
| Dr. Alana Keller, Od, OD | Optometrist | Wildwood, MO | $86,497 | $0 |
| Deepan Selvadurai, Md, MD | Ophthalmology | Orchard Park, NY | $78,895 | $0 |
| Susan Resnick, Od, OD | Optometrist | New York, NY | $78,871 | $0 |
| Dr. James Murphy, M.d, M.D | Ophthalmology | Hamden, CT | $74,384 | $0 |
| Unknown Provider | — | — | $72,888 | $0 |
| Dr. Marc Bloomenstein, Od, OD | Corneal and Contact Management | Scottsdale, AZ | $71,742 | $0 |
| Dr. Jane Dillon, Md, MD | Otolaryngology | Ormond Beach, FL | $69,945 | $0 |
| Amir Cohen, Md, MD | Ophthalmology | New Haven, CT | $65,513 | $0 |
| Jennifer Loh, M.d, M.D | Ophthalmology | Miami, FL | $65,209 | $0 |
| Dr. Blake Williamson, M.d., M.p.h., M.s, M.D., M.P.H., M.S | Ophthalmology | Baton Rouge, LA | $64,000 | $0 |
Ad
Top Products
- OMNI(R) SURGICAL SYSTEM (US) $2.7M
- TearCare SmartLid $2.5M
Associated Products (9)
- OMNI(R) SURGICAL SYSTEM (US) $2.7M
- TearCare SmartLid $2.5M
- OMNI $1.9M
- TearCare $1.8M
- OMNI SURGICAL SYSTEM $1.8M
- TEARCARE SYSTEM $1.6M
- OMNI Surgical System $198,825
- VISCO360 $44,923
- TRAB360 $28,820
Payment Categories
- Food & Beverage $1.8M
- Consulting $3.2M
- Travel & Lodging $164,362
- Research $5.4M
About Sight Sciences, Inc.
Sight Sciences, Inc. has made $12.6M in payments to 12,432 healthcare providers, recorded across 40,530 transactions in the CMS Open Payments database. In 2024, the company paid $1.3M. The top product by payment volume is OMNI(R) SURGICAL SYSTEM (US) ($2.7M).
Payments were distributed across 79 medical specialties. The top specialty by payment amount is Ophthalmology ($4.2M to 4,421 doctors).
Payment categories include: Food & Beverage ($1.8M), Consulting ($3.2M), Research ($5.4M), Travel & Lodging ($164,362).
Sight Sciences, Inc. is associated with 9 products in the CMS Open Payments database, including OMNI(R) SURGICAL SYSTEM (US), TearCare SmartLid, and OMNI.